Mostrar el registro sencillo del ítem

dc.contributor.authorPastor Idoate, Salvador 
dc.contributor.authorRedruello Guerrero, Pablo
dc.contributor.authorJuan Hernández, Laura de
dc.contributor.authorBenites Narcizo, Gregorio
dc.contributor.authorRivera Izquierdo, Mario
dc.contributor.authorGarcía Arumí, José
dc.contributor.authorPastor Jimeno, José Carlos 
dc.date.accessioned2025-10-07T11:35:08Z
dc.date.available2025-10-07T11:35:08Z
dc.date.issued2025
dc.identifier.citationActa Ophthalmologica, 2025, p. 1-25es
dc.identifier.issn1755-375Xes
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/78399
dc.descriptionProducción Científicaes
dc.description.abstractPurpose This systematic review aims to evaluate and synthesize the existing literature on the interventions used for submacular haemorrhage (SMH), highlighting the controversies and differences in clinical practice. Method A systematic review was conducted following the PRISMA guidelines. A comprehensive search was performed across multiple databases, including MEDLINE, EMBASE and Cochrane Library, to identify studies on SMH treatment. Inclusion criteria encompassed randomized controlled trials, cohort studies and case series that focused on different therapeutic interventions. Data on functional outcomes, efficacy and safety of the interventions were extracted and analysed. Results The review included 150 studies, of which 38 were included in the network meta-analysis. The analysis of best corrected visual acuity (BCVA) Included 26 studies, 20 interventions and 2125 eyes. Heterogeneity was moderate (I2 = 28.9%). Non-vitrectomy therapies showed better BCVA outcomes and fewer complications (e.g. retinal detachment, vitreous haemorrhage), while vitrectomy-based treatments achieved better anatomical results. According to P-score ranking, “Observation” had the highest probability of being most effective for BCVA (P-score = 0.8051), followed by anti-VEGF monotherapy and non-vitrectomy combinations. However, this result should be interpreted cautiously, as the “Observation” group was based on only two studies (26 eyes) with clinical heterogeneity. No publication bias was detected (Egger's test p = 0.582). Conclusions There is no consensus on a standard evidence-based treatment for SMH. Minimally invasive strategies are promising, but factors such as timing, lesion size and anti-VEGF use remain critical. Further large-scale randomised trials are needed to define optimal management.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherWileyes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectDegeneración macular relacionada con la edades
dc.subjectFactor de crecimiento endotelial antivasculares
dc.subjectVitrectomía pars planaes
dc.subjectDesplazamiento neumáticoes
dc.subjectVasculopatía coroidea polipoidees
dc.subjectHemorragia submaculares
dc.subjectHemorragia subretinianaes
dc.subjectActivador tisular del plasminógenoes
dc.titleInterventions for submacular haemorrhage: A systematic review and network meta‐analysis of controversies—On behalf of the Spanish Vitreo‐Retinal Society (SERV)es
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2025 The Author(s)es
dc.identifier.doi10.1111/AOS.17570es
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/aos.17570es
dc.identifier.publicationfirstpage1es
dc.identifier.publicationlastpage25es
dc.identifier.publicationtitleActa Ophthalmologicaes
dc.peerreviewedSIes
dc.description.projectOpen access funding provided by FEDER European Funds and the Junta De Castilla y León under the Research and Innovation Strategy for Smart Specialization (RIS3) of Castilla y León 2021-2027.es
dc.identifier.essn1755-3768es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem